Moving from 2.5mg to 5mg Mounjaro: making the decision

Why 2.5mg exists and what changes at 5mg

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, which together slow gastric emptying, reduce appetite and influence blood-sugar regulation. The 2.5mg dose is low enough that most people's digestive systems can adapt without significant disruption — but it is also too low to produce meaningful appetite reduction for most people. Think of those first four weeks as your system finding its footing.

At 5mg, the pharmacological effect strengthens noticeably. Appetite suppression becomes more consistent, and the characteristic feeling of fullness after smaller portions tends to arrive. Clinical trial data published in the New England Journal of Medicine showed that the weight-loss outcomes in the SURMOUNT-1 programme (reaching an average of around 20% body-weight reduction at the highest doses) were built through this stepwise titration, not through any single dose. The 5mg pen is effectively where that process starts in earnest.

It is also worth knowing that moving from 2.5 to 5mg Mounjaro does not change the injection device, the injection-day routine, or storage. The pen still needs to live in the fridge (2–8°C), and the once-weekly habit you have already established carries straight across. For dosing specifics and storage windows, the Mounjaro SmPC on the eMC is the authoritative reference. Details about what the 5mg pen involves are covered separately if you want to read ahead.

How your prescriber decides you are ready

The four-week window before moving up is a minimum, not an instruction to increase automatically. Your prescriber will want to know two things: how well you tolerated 2.5mg, and whether there are any reasons to pause before going further.

Tolerability is assessed on the severity and duration of gastrointestinal symptoms. Nausea, loose stools, burping and reduced appetite are all common at the start of tirzepatide treatment; they are expected, and they usually settle. If they were still severe by week three or four, delaying the increase and staying on 2.5mg longer is a reasonable clinical choice. Rushing the step-up when your digestive system has not yet settled tends to amplify the side effects that come with any dose increase.

Conversely, if 2.5mg was well tolerated from week one and side effects faded quickly, moving up to 5mg Mounjaro after four weeks is standard. The NHS guidance on weight-management injections describes this kind of careful titration as integral to safe use, not as optional caution. At nume, every repeat and dose-increase request is reviewed by a GPhC-registered Independent Prescriber; a real clinician reads your notes before any change is confirmed. That review process is part of what the consultation covers from the outset.

What to expect when you step up, and when to get help

Side effects at 5mg often mirror what you experienced in the first days of 2.5mg, just briefly restarted. Nausea is the most commonly reported symptom; it typically peaks in the first few days after the new dose and fades within a week to two weeks for most people. Eating smaller meals, avoiding very fatty or rich food in the days after the step-up, and staying well hydrated all reduce the likelihood of discomfort persisting.

Fatigue and mild headache are also reported during titration and tend to resolve as the body adjusts. These are documented in the NHS tirzepatide medicines page and are not, on their own, a sign that the dose is unsuitable for you.

Certain symptoms should prompt you to contact a healthcare professional promptly rather than waiting them out. Severe and persistent abdominal pain, particularly if it radiates toward the back, is something to take seriously, the MHRA highlighted acute pancreatitis as an infrequent but serious known risk for GLP-1 medicines in a January 2026 Drug Safety Update. Significant dehydration from repeated vomiting or diarrhoea is another reason to seek advice rather than persevere. If you are a nume patient, our aftercare team is available seven days a week. And any suspected side effect can be reported directly to the MHRA via the Yellow Card scheme.

What comes after 5mg

Stepping up to 5mg is one rung in a titration schedule that can continue, in four-week steps, through 7.5mg, 10mg, 12.5mg and up to 15mg, each increase only if the previous dose was well tolerated and a prescriber judges it appropriate. Not everyone reaches 15mg; some people find a lower maintenance dose effective and prefer to stay there.

The decision framework at each step is the same one you face now: has the current dose settled? Are side effects manageable? Is there clinical reason to continue upward? If you are curious about what the next step involves, the page on moving to 7.5mg covers that transition in the same detail, and you may also find it helpful to read about moving up to 10mg Mounjaro so you have a sense of the broader titration journey ahead. There is also a useful FAQ resource on our general FAQs page for common questions that come up between reviews.

For now, the 2.5mg to 5mg move is the one that matters. Get it right (good tolerance, clear communication with your prescriber, and realistic expectations about the brief side-effect restart) and the rest of the titration tends to follow more smoothly. If you are starting Mounjaro or moving between doses and want a same-day clinical review, you can start your free consultation with our prescribing team today.